Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 16/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22981943 | 0.84 | FLT3 (0.52) | NR2E1FLT3RAF1NPBWR1 | |
| SCHEMBL31289487 | 0.81 | MEN1 (0.50) | NPBWR1 | |
| SCHEMBL29848766 | 0.81 | FLT3 (0.54) | NR2E1FLT3RAF1NPBWR1 | |
| SCHEMBL29848555 | 0.81 | NR2E1 (0.54) | NR2E1FLT3RAF1PSEN1PSEN2 | |
| SCHEMBL29848642 | 0.81 | FLT3 (0.55) | NR2E1FLT3NPBWR1 | |
| SCHEMBL23010723 | 0.81 | NR2E1 (0.54) | NR2E1FLT3RAF1PSEN1PSEN2 | |
| SCHEMBL29529143 | 0.80 | NR2E1 (0.58) | NR2E1FLT3RAF1PSEN1PSEN2 | |
| SCHEMBL26674969 | 0.80 | NR2E1 (0.58) | NR2E1FLT3RAF1PSEN1PSEN2 | |
| SCHEMBL29848634 | 0.78 | DGAT1 (0.56) | FLT3 | |
| SCHEMBL589390 | 0.77 | NR2E1 (1.00) | NR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473278-B2 | Imidazole derivative expressing FLT3 inhibitory activity, and use thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2025-11-18 | — | — | US | disclosed |
| US-20220315573-A1 | Novel Imidazole Derivative Expressing FLT3 Inhibitory Activity, and Use Thereof | Industry-University Cooperation Foundation Hangyang University Erica Campus (KR) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315573-A1 | Novel Imidazole Derivative Expressing FLT3 Inhibitory Activity, and Use Thereof | FLT3, FLI1, MCL1 | NR2E1 2765/4885FLT3 1/4885RAF1 457/4885 |
| US-12473278-B2 | Imidazole derivative expressing FLT3 inhibitory activity, and use thereof | FLT3, FLI1, MCL1 | NR2E1 2643/4885FLT3 1/4885RAF1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.